https://www.makeeyeware.com必威手机APPinsight
//www.makeeyeware.comTaplow
//www.makeeyeware.comKnowledge
  • 消息
  • 案例
  • 下载
Taplow Group – 11th 2020 Global Business Overview
30.11.2020

Taplow Group – 11th 2020 Global Business Overview

Taplow global partners bring you local and regional economic and business insights, aiding business leaders, gather information...
Taplow Group  -  2020年10月10日全球业务概述
02.11.2020

Taplow Group - 2020年10月10日全球业务概述

全球大流行企业影响cross every sector, in all parts of the world. Taplow partners across the globe have combined to...
Taplow Group  -  2020年全球业务概述
05.10.2020

Taplow Group - 2020年全球业务概述

Taplow公司在整个大流行中一直活跃。这是我们合作伙伴围绕...的业务更新系列中的第九个更新。
1 2 3 4 5 6 7 8 9 10 Last

CEO FOR A SPORTS:

情况:一家芬兰人,主要是全国运营的体育公司,需要新任首席执行官,因为旧的首席执行官即将退休。由于体育业务是我们芬兰合作伙伴的能力领域之一,因此我们最终进行了搜索。

阅读更多 …

For further Information please contac芬兰的蒂莫·托瓦宁(Timo Toivanen)

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

阅读更多 …

For further Information please contac芬兰的蒂莫·托瓦宁(Timo Toivanen)

白皮书
  • 印度 - 新型汽车的研发枢纽

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact印度Sangeeta Sabharwal

    Click Here
  • Maysam Rizvi回顾了银行技术革命。

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • 不断发展的业务部门市场进入,因此成为“横向”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here